Investment Bank Mizuho Initiates Coverage of Exact Sciences with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Mizuho Securities USA has initiated coverage of Exact Sciences with a Buy rating and a $13 price target.

The Madison, Wis.-based firm is developing the Cologuard test, a stool-based DNA test for colorectal cancer screening. Mizuho analyst Peter Lawson said in a note that there is a "large untapped revenue opportunity available to Cologuard of over $1.2 billion in the US with limited competition."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.